BioSpace News Archive

Study to evaluate the Company’s Thin Film Freezing technology to formulate dry powder universal influenza vaccines for pulmonary delivery

PDS Biotechnology Corporation today announced that it has appointed Ilian Iliev, Ph.D. to its Board of Directors. “We are very pleased to welcome Dr. Iliev to the Board of Directors. He brings a wealth of experience to PDS Biotech as a recognized entrepreneur and venture capital

Quest International, Inc., the global leading service provider specializing in depot repairs, field services, and supply chain logistics for medical device manufacturers, announced the expansion of their ISO 13485 certified service infrastructure in response to the surge in demand for the assembly and servicing of ventilators and related critical medical devices due to COVID-19.

LabLynx, Inc., long-time leader in enterprise-level cloud-hosted LIMS/LIS, today announced it has developed the world’s first LIMS (Laboratory Information Management System) dedicated specifically to COVID-19 diagnostic testing.

Glaukos Corporation today provided an update on the impact of the COVID-19 pandemic on the company and announced a preliminary net sales range for its first quarter of 2020. Preliminary and Unaudited First Quarter 2020 Net Sales and COVID-19

Horizon Therapeutics plc (NASDAQ:HZNP) today announced it has been selected as one of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®.

“Today, the Government of Canada released national-level modelling on the COVID-19 epidemic in Canada. The modelling attempts to show how the epidemic might unfold over the coming months based on our knowledge of how the virus behaves and the potential impact of public health measures.

CrossRoads® Extremity Systems announces the launch of miniBunion™, a minimally-invasive technique and system to repair painful bunions.

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the combination of NeoImmuneTech’s NT-I7 (also known as Hyleukin-7™), a long-acting IL-7, and Bristol Myers Squibb’s Opdivo® (nivolumab), a PD-1 blocking antibody. The goal of the Phase 2 study is to establish safety

Groundbreaking Registry Aims to Help Researchers Accelerate COVID-19 Diagnosis, Treatment and Prevention Strategies